SCHEMBL9879490

SCHEMBL9879490

CSC(=N)NC(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9424822 0.97
SCHEMBL22149621 0.80
SCHEMBL18480083 0.76
SCHEMBL11674827 0.76 ALDH1A1 (0.38)
SCHEMBL23838288 0.73
SCHEMBL18481665 0.71
SCHEMBL3080618 0.69 CA12 (0.34)
SCHEMBL3072893 0.69
SCHEMBL230050 0.67 CA12 (0.35)
SCHEMBL18928827 0.67 ALDH1A1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024084390-A1 COMPOUNDS FOR THE ACTIVATION OF AMPK PFIZER INC. (US) 2024-04-25 WO disclosed
US-20230028441-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES ELANCO ANIMAL HEALTH GMBH (DE) 2023-01-26 US disclosed
EP-3885346-A1 AMINOPYRIMIDINE COMPOUND USED FOR INHIBITING ACTIVITY OF PROTEIN KINASE Shenzhen TargetRx, Inc. (CN) 2021-09-29 EP disclosed
WO-2021069567-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2021-04-15 WO disclosed
US-10787419-B2 Cannabinoid receptor mediating iminopyrazole compounds THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-09-29 US disclosed
WO-2019242587-A1 HIGHLY SELECTIVE FGFR I INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2019-12-26 WO disclosed
EP-2994127-B1 FURANONE COMPOUNDS AS KINASE INHIBITORS ETERNITY BIOSCIENCE INC (US) 2019-10-09 EP disclosed
US-20190076406-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2019-03-14 US disclosed
US-20180022705-A1 CANNABINOID RECEPTOR MEDIATING COMPOUNDS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2018-01-25 US disclosed
US-20160279104-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-09-29 US disclosed
US-20140170160-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR MASSACHUSETTS EYE & EAR INFIRMARY (US) 2014-06-19 US disclosed
US-20120276111-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-11-01 US disclosed
US-20120276111-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP-1) INHIBITOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-11-01 US disclosed
US-7700577-B2 Carbohydrate based anti-bacterials ALCHEMIA LIMITED (AU) 2010-04-20 US disclosed
US-20090170770-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH ANGIOGENESIS USING A VASCULAR ADHESION PROTEIN-1 (VAP 1) INHIBITOR NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-07-02 US disclosed
WO-1991018885-A1 IMIDAZOLES FOR THE TREATMENT OF ATHEROSCLEROSIS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1991-12-12 WO disclosed
US-4141899-A ANTIULCER, ANTISECRETORY SOCIETA' FARMACEUTICI ITALIA S.P.A. (IT) 1979-02-27 US disclosed